Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

by on 7 de novembre de 2022 with No hi ha comentaris
  • Le Tourneau, C., Becker, H., Claus, R., Elez, E., Ricci, F., Fritsch, R., Tabernero, J., . . . Isambert, N. (2022). Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors. ESMO Open, 7(5). https://doi.org/10.1016/j.esmoop.2022.100576

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *